

Subarachnoid haemorrhage

[G] Evidence review for detecting hydrocephalus

NICE guideline <number>

Evidence review underpinning

February 2021

Draft for Consultation

*This evidence review was developed by
the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2020. All rights reserved. Subject to Notice of rights.

ISBN

[add for final publication version only, delete this text for consultation version]

Contents

1	Detecting hydrocephalus	5
1.1	Review question: What is the diagnostic accuracy of investigations for detecting hydrocephalus for the person with aSAH and signs of neurological deterioration?	5
1.2	Introduction	5
1.3	PICO table.....	5
1.4	Clinical evidence	6
1.4.1	Included studies	6
1.4.2	Excluded studies.....	6
1.4.3	Summary of clinical studies included in the evidence review.....	7
1.4.4	Quality assessment of clinical studies included in the evidence review	7
1.5	Economic evidence	8
1.5.1	Included studies	8
1.5.2	Excluded studies.....	8
1.5.3	Unit costs	8
1.6	Evidence statements	8
1.6.1	Clinical evidence statements.....	8
1.6.2	Health economic evidence statements.....	8
1.7	The committee’s discussion of the evidence.....	8
1.7.1	Interpreting the evidence.....	8
1.7.2	Cost effectiveness and resource use	10
1.7.3	Other factors the committee took into account	10
	Appendices	12
	Appendix A: Review protocols	12
	Appendix B: Literature search strategies	18
	B.1 Clinical search literature search strategy	18
	B.2 Health Economics literature search strategy.....	23
	Appendix C: Clinical evidence selection.....	27
	Appendix D: Clinical evidence tables	28
	Appendix E: Coupled sensitivity and specificity forest plots and sROC curves.....	29
	Appendix F: Health economic evidence selection	30
	Appendix G: Health economic evidence tables	32
	Appendix H: Excluded studies.....	33
	H.1 Excluded clinical studies.....	33
	H.2 Excluded health economic studies.....	33

1 ¹ Detecting hydrocephalus

² Evidence review underpinning recommendation 1.3.3 in the NICE guideline.

1.1 ³ Review question: What is the diagnostic accuracy of ⁴ investigations for detecting hydrocephalus for the person ⁵ with aSAH and signs of neurological deterioration?

1.2 ⁶ Introduction

⁷ Hydrocephalus is diagnosed when a patient presents with symptoms and signs of raised
⁸ intracranial pressure and axial imaging of the brain shows enlargement of the ventricular
⁹ system (the fluid filled chambers within the brain). Ventricular dimensions can be assessed
¹⁰ equally effectively on CT and MRI but imaging evidence of ventricular enlargement alone is
¹¹ insufficient to diagnose hydrocephalus, as enlarged ventricles may be long-standing in some
¹² people.

¹³ Up to a third of patients with aneurysmal SAH develop acute hydrocephalus within a few
¹⁴ days of presentation, and the dimensions of the ventricular system are generally assessed
¹⁵ on a non-contrast CT scan, and correlated with previous CT imaging (if available) and the
¹⁶ patient's clinical status.

¹⁷ The pathogenesis of hydrocephalus in people with aSAH is complex, but thought to be due
¹⁸ to obstruction of CSF flow, or reduction of CSF reabsorption. The probability of developing
¹⁹ hydrocephalus is increased when SAH is associated with: worse clinical grade, large volume
²⁰ of blood in the basal cisterns, intra-ventricular haemorrhage, posterior circulation aneurysm,
²¹ or systemic hypertension.

²² Up to half of patients with a reduced GCS score due to acute hydrocephalus will improve
²³ without surgical management but comatose patients require prompt ventricular drainage.

²⁴ A proportion of patients with acute hydrocephalus will go on to develop chronic (shunt-
²⁵ dependent) hydrocephalus and may require longer term CSF diversion, usually with a
²⁶ ventriculo-peritoneal shunt.

²⁷ This evidence review was carried out to assess the diagnostic accuracy of MR imaging for
²⁸ the detection of hydrocephalus in people with aneurysmal SAH, relative to the reference
²⁹ standard of non-contrast CT.

1.3 ³⁰ PICO table

³¹ For full details see the review protocol in Appendix A:.

³² **Table 1: PICO characteristics of review question**

Population	Inclusion: Adults (16 and older) with a confirmed subarachnoid haemorrhage caused by a ruptured aneurysm and with signs of neurological deterioration. Exclusion: <ul style="list-style-type: none">• Adults with subarachnoid haemorrhage caused by head injury, ischaemic stroke or an arteriovenous malformation.• Children and young people aged 15 years and younger.
Target condition	Acute hydrocephalus in people with aneurysmal subarachnoid haemorrhage
Index test(s) (comparator(s))	MRI

Reference standard(s)	Non-Contrast CT
Statistical measures [or] Outcomes	Statistical measure to detect hydrocephalus: <ul style="list-style-type: none">• Sensitivity• Specificity
Study design	<ul style="list-style-type: none">• Cross-sectional studies• Cohort studies• Systematic reviews of observational cohort studies will be included

1.4 1 Clinical evidence

1.4.1 2 Included studies

3 No relevant diagnostic accuracy studies of MR imaging to detect hydrocephalus in people
4 with aSAH were identified.

5 See also the study selection flow chart in Appendix C:.

1.4.2 6 Excluded studies

7 See the excluded studies list in Appendix H:.

8

1.4.3 1 Summary of clinical studies included in the evidence review

2 No evidence was identified for this review.

1.4.4 3 Quality assessment of clinical studies included in the evidence review

4 No evidence was identified for this review.

5

1.5 1 Economic evidence

1.5.1 2 Included studies

3 No health economic studies were included.

1.5.2 4 Excluded studies

5 No relevant health economic studies were excluded due to assessment of limited
6 applicability or methodological limitations.

7 See also the health economic study selection flow chart in Appendix F:.

1.5.3 8 Unit costs

9 Relevant unit costs are provided in Table 2 to aid consideration of cost effectiveness.

10 **Table 2: UK costs of diagnostic tests for aneurysmal subarachnoid haemorrhage**

Diagnostic test description	Cost
Computerised Tomography Scan of One Area, without Contrast, 19 years and over [NHS Reference cost code: RD20A]	£78
Magnetic Resonance Imaging Scan of One Area, without Contrast, 19 years and over [NHS Reference cost code: RD01A]	£121

11 *Source: NHS Reference Costs 2018/19⁶*

1.6 12 Evidence statements

1.6.1 13 Clinical evidence statements

14 No evidence was identified for this review

1.6.2 15 Health economic evidence statements

16 No relevant economic evaluations were identified.

1.7 17 The committee's discussion of the evidence

1.7.1 18 Interpreting the evidence

1.7.1.1 19 The diagnostic measures that matter most

20 The objective of this review was to assess the diagnostic accuracy of MR imaging for
21 detecting hydrocephalus, relative to a reference standard of CT head scan. Sensitivity and
22 specificity of MRI imaging to detect hydrocephalus were the outcomes for this review.

1.7.1.2 23 The quality of the evidence

24 No evidence was identified for this review. The committee made a consensus
25 recommendation reflecting standard current practice on the use of comparative CT head
26 scans to confirm a diagnosis of hydrocephalus.

1.7.1.3 1 Benefits and harms

2 The committee agreed that hydrocephalus is suspected on the basis of symptoms and signs
3 of raised intracranial pressure, such as altered level of consciousness or neurological
4 deterioration. In current practice a diagnosis of hydrocephalus is confirmed by enlargement
5 of the ventricular system on a CT head scan in comparison with previous CT head scans or
6 other brain imaging. The main benefit of detecting hydrocephalus as the cause of acute
7 neurological deterioration is to enable diversion or drainage of CSF, to reduce the pressure
8 on the brain, and relieve symptoms (such as headache, nausea, impaired vision, and
9 reduced mobility).

10 Acute hydrocephalus:

11 Acute neurological deterioration in a person with aSAH is a medical emergency and needs
12 rapid assessment and management. In current practice, patients with acute neurological
13 deterioration are investigated with a CT head scan to exclude other causes of deterioration
14 (such as further bleeding), and allow comparison with previous CT head scans or other
15 imaging to detect enlargement of the ventricular system. From their clinical experience the
16 committee agreed that acute hydrocephalus is common in people with aSAH and timely
17 investigation and diagnosis are important to facilitate treatment and avoid disability and
18 death. The committee highlighted that clinical judgment should be used to determine if the
19 interval between comparative CT scans is sufficient to demonstrate ventricular enlargement
20 and confirm a diagnosis of acute hydrocephalus. The committee made a consensus
21 recommendation to diagnose acute hydrocephalus using a comparative review of current
22 and previous CT or other brain imaging.

23 Chronic hydrocephalus:

24 From their experience the committee noted that chronic hydrocephalus is uncommon and
25 typically presents several weeks or months after aSAH with reduced consciousness, gait
26 disturbance or other neurological symptoms. The committee acknowledged that in current
27 practice a person with suspected chronic hydrocephalus late after aSAH will generally be
28 investigated with a CT brain scan to assess ventricular dimensions. The committee agreed
29 that a diagnosis of chronic hydrocephalus should take account of the person's clinical
30 condition and the radiological findings, including a comparative review of a current CT head
31 scan and previous CT or other brain imaging. As such, the committee made a second
32 consensus recommendation to diagnose chronic hydrocephalus taking account of the
33 person's symptoms and signs and radiological evidence using a comparative review of
34 current and previous CT or other brain imaging.

35 The committee discussed the potential role of MR imaging in the investigation of people with
36 aSAH and suspected hydrocephalus. The committee agreed a CT scan is safer than MR
37 imaging in a person with signs of neurological deterioration. MR scans take longer and the
38 patient is enclosed within the scanner, which limits access to an intubated patient or in an
39 emergency situation. The committee considered MR imaging to be a difficult procedure to
40 undertake in a person who is unwell and CT is the most efficient diagnostic imaging modality
41 for suspected hydrocephalus in people with aSAH and acute neurological deterioration. For
42 these reasons the committee agreed to make a strong recommendation to diagnose
43 hydrocephalus with CT head scan and agreed that a research recommendation for the use of
44 MR imaging in the diagnosis of hydrocephalus was unwarranted.

45 In a separate review of the management of acute and chronic hydrocephalus, the committee
46 made consensus recommendations to consider drainage or diversion of cerebrospinal fluid
47 for people with neurological deterioration caused by hydrocephalus.

48

1.7.2 1 Cost effectiveness and resource use

2 No published economic evidence was identified for this review. Unit costs were presented to
3 the committee for consideration of cost effectiveness.

4 The committee considered a non-contrast CT scan to be the reference standard and hence
5 most accurate imaging modality for detecting hydrocephalus. Given that a non-contrast CT
6 scan is less costly than an MRI scan, the committee considered a non-contrast CT scan to
7 be the most cost-effective imaging modality for detecting hydrocephalus. Moreover, in most
8 patients a CT scan can be compared directly with the diagnostic CT scan recorded on initial
9 presentation with suspected subarachnoid haemorrhage.

10 The committee noted that this is current practice and so do not expect the recommendations
11 to have a substantial resource impact for England.

1.7.3 2 Other factors the committee took into account

13 The committee also considered that CT imaging may be more readily available than MRI
14 imaging in an acute setting in the NHS in England.
15

1 References

- 2 1. Andaluz N, Zuccarello M. Yield of further diagnostic work-up of cryptogenic
3 subarachnoid hemorrhage based on bleeding patterns on computed tomographic
4 scans. *Neurosurgery*. 2008; 62(5):1040-1046; discussion 1047
- 5 2. Duong H, Melancon D, Tampieri D, Ethier R. The negative angiogram in
6 subarachnoid haemorrhage. *Neuroradiology*. 1996; 38(1):15-19
- 7 3. Łuczywek E, Fersten E, Zabołotny W, Szeląg E, Czernicki Z. Assessment of blood
8 flow velocity during cognitive stimulation in persons with suspected hydrocephalus.
9 *Neurologia i Neurochirurgia Polska*. 2000; 34(5):887-897
- 10 4. Mortimer AM, Steinfort B, Faulder K, Harrington T. Delayed infarction following
11 aneurysmal subarachnoid hemorrhage: can the role of severe angiographic
12 vasospasm really be dismissed? *Journal of Neurointerventional Surgery*. 2016;
13 8(8):802-807
- 14 5. National Institute for Health and Care Excellence. Developing NICE guidelines: the
15 manual [updated October 2018]. London. National Institute for Health and Care
16 Excellence, 2014. Available from:
17 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 18 6. NHS England and NHS Improvement. National cost collection for the NHS 2018-19.
19 2019. Available from: <https://improvement.nhs.uk/resources/national-cost-collection/>
20 Last accessed: 01/04/2020.
- 21 7. Ohmichi T, Kondo M, Itsukage M, Koizumi H, Matsushima S, Kuriyama N et al.
22 Usefulness of the convexity apparent hyperperfusion sign in 123I-iodoamphetamine
23 brain perfusion SPECT for the diagnosis of idiopathic normal pressure
24 hydrocephalus. *Journal of Neurosurgery*. 2018; 130(2):398-405
- 25 8. Pascual J, Gonzalez-Mandly A, Martin R, Oterino A. Headaches precipitated by
26 cough, prolonged exercise or sexual activity: a prospective etiological and clinical
27 study. *Journal of Headache and Pain*. 2008; 9(5):259-266
- 28 9. Peschillo S, Caporlingua A, Resta MC, Paul Peluso JP, Burdi N, Sourour N et al.
29 Endovascular treatment of large and giant carotid aneurysms with flow-diverter stents
30 alone or in combination with coils: a multicenter experience and long-term follow-up.
31 *Operative Neurosurgery*. 2017; 13(4):492-502
- 32 10. Stadlbauer A, Salomonowitz E, Brenneis C, Ungersbock K, van der Riet W,
33 Buchfelder M et al. Magnetic resonance velocity mapping of 3D cerebrospinal fluid
34 flow dynamics in hydrocephalus: preliminary results. *European Radiology*. 2012;
35 22(1):232-242
- 36 11. Woodfield J, Rane N, Cudlip S, Byrne JV. Value of delayed MRI in angiogram-
37 negative subarachnoid haemorrhage. *Clinical Radiology*. 2014; 69(4):350-356

38

39

1 Appendices

2 Appendix A: Review protocols

3 **Table 3: Review protocol: Detecting hydrocephalus**

Field	Content
PROSPERO registration number	CRD42020177951
Review title	What is the diagnostic accuracy of investigations for detecting hydrocephalus for the person with aSAH and signs of neurological deterioration?
Review question	What is the diagnostic accuracy of investigations for detecting hydrocephalus for the person with aSAH and signs of neurological deterioration?
Objective	To determine which investigation is the most accurate to detect hydrocephalus in a person with aSAH and signs of neurological deterioration.
Searches	<p>The following databases (from inception) will be searched:</p> <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Embase • MEDLINE <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language studies • Human studies <p>The full search strategies will be published in the final review.</p>
Condition or domain being studied	Acute hydrocephalus in people with aneurysmal subarachnoid haemorrhage
Population	<p>Inclusion: Adults (16 and older) with a confirmed subarachnoid haemorrhage caused by a ruptured aneurysm and with signs of neurological deterioration.</p> <p>Exclusion:</p> <ul style="list-style-type: none"> • Adults with subarachnoid haemorrhage caused by head injury, ischaemic stroke or an arteriovenous malformation. • Children and young people aged 15 years and younger.
Index test	<ul style="list-style-type: none"> • MRI
Reference standard	<ul style="list-style-type: none"> • Non-contrast CT
Types of study to be included	<ul style="list-style-type: none"> • Cross-sectional studies • Cohort studies

	<ul style="list-style-type: none"> • Systematic reviews of observational cohort studies will be included.
Other exclusion criteria	<p>Exclusions:</p> <ul style="list-style-type: none"> • Studies that do not report sensitivity and specificity, or insufficient data to derive these values. • Non English language studies.
Context	<p>Hydrocephalus is a serious complication of aSAH. In clinical practice, a person with aSAH who is deteriorating neurologically will undergo investigatory tests to determine the cause of deterioration. In current practice the first line investigation will be a non-contrast CT head. The diagnosis accuracy of tests to hydrocephalus will allow for appropriate investigations of the deteriorating person.</p>
Primary outcomes (critical outcomes)	<p>Statistical measure to detect hydrocephalus:</p> <ul style="list-style-type: none"> • Sensitivity • Specificity
Secondary outcomes (important outcomes)	<p>Statistical measure to detect hydrocephalus:</p> <ul style="list-style-type: none"> • Positive Predictive Value (PPV) • Negative Predictive Value (NPV) • Receiver Operating Characteristic (ROC) curve or area under curve
Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>A standardised form will be used to extract data from studies (see Developing NICE guidelines: the manual section 6.4).</p>
Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <p>Diagnostic test accuracy studies risk of bias will be assessed using QUADAS-2.</p> <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> • papers were included /excluded appropriately • a sample of the data extractions • correct methods are used to synthesise data • a sample of the risk of bias assessments <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>

Strategy for data synthesis	Aggregate data on diagnostic accuracy of investigations will be collected and synthesized in a quantitative data analysis. Endnote will be used for bibliography, citations, sifting and reference management. WinBUGS will be used for meta-analysis of diagnostic accuracy studies if included studies are sufficiently homogeneous. Where meta-analysis cannot be performed results will be reported in full on a per-study basis and summary values will be presented as median values. A summary of result will be presented following a modified GRADE approach. Data synthesis will be completed by two reviewers, with any disagreements resolved by discussion, or if necessary a third independent reviewer.		
Analysis of sub-groups	None		
Type and method of review	<input type="checkbox"/>	Intervention	
	<input checked="" type="checkbox"/>	Diagnostic	
	<input type="checkbox"/>	Prognostic	
	<input type="checkbox"/>	Qualitative	
	<input type="checkbox"/>	Epidemiologic	
	<input type="checkbox"/>	Service Delivery	
	<input type="checkbox"/>	Other (please specify)	
Language	English		
Country	England		
Anticipated or actual start date			
Anticipated completion date	3 February 2021		
Stage of review at time of this submission	Review stage	Started	Completed
	Preliminary searches	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Piloting of the study selection process	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Formal screening of search results against eligibility criteria	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Data extraction	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Risk of bias (quality) assessment	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Data analysis	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Named contact	5a. Named contact National Guideline Centre		

	<p>5b Named contact e-mail</p> <p>SAH@nice.org.uk</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>
Review team members	<p>From the National Guideline Centre:</p> <ul style="list-style-type: none"> • Ms Gill Ritchie • Mr Ben Mayer • Mr Audrius Stonkus • Mr Vimal Bedia • Ms Emma Cowles • Ms Jill Cobb • Ms Amelia Unsworth
Funding sources/sponsor	<p>This systematic review is being completed by the National Guideline Centre which receives funding from NICE.</p>
Conflicts of interest	<p>All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.</p>
Collaborators	<p>Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual. Members of the guideline committee are available on the NICE website.</p>
Other registration details	
Reference/URL for published protocol	
Dissemination plans	<p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts

	<ul style="list-style-type: none"> • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE. 	
Keywords	Subarachnoid haemorrhage, hydrocephalus, computed tomography, MRI	
Details of existing review of same topic by same authors	None	
Current review status	<input type="checkbox"/>	Ongoing
	<input type="checkbox"/>	Completed but not published
	<input type="checkbox"/>	Completed and published
	<input type="checkbox"/>	Completed, published and being updated
	<input type="checkbox"/>	Discontinued
Additional information		
Details of final publication	www.nice.org.uk	

1

1 Table 4: Health economic review protocol

Review question	All questions where health economic evidence applicable
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual.⁵</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will decide based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p> <p>The health economist will be guided by the following hierarchies.</p> <p><i>Setting:</i></p> <ul style="list-style-type: none"> • UK NHS (most applicable). • OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).

- OECD countries with predominantly private health insurance systems (for example, Switzerland).
 - Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.
- Health economic study type:*
- Cost–utility analysis (most applicable).
 - Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
 - Comparative cost analysis.
 - Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.
- Year of analysis:*
- The more recent the study, the more applicable it will be.
 - Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as ‘Not applicable’.
 - Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.
- Quality and relevance of effectiveness data used in the health economic analysis:*
- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

2 **Appendix B: Literature search strategies**

3 This literature search strategy was used for the following review;

- 4 • What is the diagnostic accuracy of investigations for detecting hydrocephalus for the
 5 person with aSAH and signs of neurological deterioration?
 6

7 The literature searches for this review are detailed below and complied with the methodology
 8 outlined in Developing NICE guidelines: the manual⁵

9 For more information, please see the Methods Report published as part of the accompanying
 10 documents for this guideline.

11 **B.1 Clinical search literature search strategy**

12 Searches were constructed using a PICO framework where population (P) terms were
 13 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are
 14 rarely used in search strategies for interventions as these concepts may not be well
 15 described in title, abstract or indexes and therefore difficult to retrieve. Search filters were
 16 applied to the search where appropriate.

17 **Table 5: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 24 June 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies Diagnostic tests studies
Embase (OVID)	1974 – 24 June 2020	Exclusions

Database	Dates searched	Search filter used
		Randomised controlled trials Systematic review studies Observational studies Diagnostic tests studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 6 of 12 CENTRAL to 2020 Issue 6 of 12	None

1 Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp Intracranial Aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
27.	25 not 26
28.	limit 27 to English language
29.	exp "Sensitivity and Specificity"/
30.	(sensitivity or specificity).ti,ab.
31.	((pre test or pretest or post test) adj probability).ti,ab.
32.	(predictive value* or PPV or NPV).ti,ab.
33.	likelihood ratio*.ti,ab.
34.	likelihood function/

35.	((area under adj4 curve) or AUC).ti,ab.
36.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
37.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
38.	gold standard.ab.
39.	or/29-38
40.	Epidemiologic studies/
41.	Observational study/
42.	exp Cohort studies/
43.	(cohort adj (study or studies or analys* or data)).ti,ab.
44.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
45.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
46.	Controlled Before-After Studies/
47.	Historically Controlled Study/
48.	Interrupted Time Series Analysis/
49.	(before adj2 after adj2 (study or studies or data)).ti,ab.
50.	exp case control study/
51.	case control*.ti,ab.
52.	Cross-sectional studies/
53.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
54.	or/40-53
55.	Meta-Analysis/
56.	exp Meta-Analysis as Topic/
57.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
58.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
59.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
60.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
61.	(search* adj4 literature).ab.
62.	(medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
63.	cochrane.jw.
64.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
65.	or/55-64
66.	randomized controlled trial.pt.
67.	controlled clinical trial.pt.
68.	randomi#ed.ti,ab.
69.	placebo.ab.
70.	randomly.ti,ab.
71.	Clinical Trials as topic.sh.
72.	trial.ti.
73.	or/66-72
74.	28 and (39 or 54 or 65 or 73)
75.	hydrocephalus/ or hydrocephalus, normal pressure/

76.	(hydrocephalus or hydrocephaly).ti,ab.
77.	water on the brain.ti,ab.
78.	or/75-77
79.	74 and 78

1 Embase (Ovid) search terms

1.	*subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	Case report/ or Case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	Nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental animal/
19.	Animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)
25.	23 not 24
26.	limit 25 to English language
27.	exp "sensitivity and specificity"/
28.	(sensitivity or specificity).ti,ab.
29.	((pre test or pretest or post test) adj probability).ti,ab.
30.	(predictive value* or PPV or NPV).ti,ab.
31.	likelihood ratio*.ti,ab.
32.	((area under adj4 curve) or AUC).ti,ab.
33.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
34.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
35.	diagnostic accuracy/
36.	diagnostic test accuracy study/
37.	gold standard.ab.

38.	or/27-37
39.	Clinical study/
40.	Observational study/
41.	family study/
42.	longitudinal study/
43.	retrospective study/
44.	prospective study/
45.	cohort analysis/
46.	follow-up/
47.	cohort*.ti,ab.
48.	46 and 47
49.	(cohort adj (study or studies or analys* or data)).ti,ab.
50.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
51.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
52.	(before adj2 after adj2 (study or studies or data)).ti,ab.
53.	exp case control study/
54.	case control*.ti,ab.
55.	cross-sectional study/
56.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
57.	or/39-45,48-56
58.	random*.ti,ab.
59.	factorial*.ti,ab.
60.	(crossover* or cross over*).ti,ab.
61.	((doubl* or singl*) adj blind*).ti,ab.
62.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
63.	crossover procedure/
64.	single blind procedure/
65.	randomized controlled trial/
66.	double blind procedure/
67.	or/58-66
68.	systematic review/
69.	meta-analysis/
70.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
71.	((systematic or evidence) adj3 (review* or overview*)).ti,ab.
72.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
73.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
74.	(search* adj4 literature).ab.
75.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
76.	cochrane.jw.
77.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
78.	or/68-77
79.	26 and (38 or 57 or 67 or 78)

80.	normotensive hydrocephalus/ or hydrocephalus/
81.	(hydrocephalus or hydrocephaly).ti,ab.
82.	water on the brain.ti,ab.
83.	or/80-82
84.	79 and 83

1 Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Subarachnoid Hemorrhage] explode all trees
#2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) near/3 (hemorrhag* or haemorrhag* or bleed* or blood*)):ti,ab
#3.	(SAH or aSAH):ti,ab
#4.	MeSH descriptor: [Intracranial Aneurysm] explode all trees
#5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) near/3 (aneurysm* or aneurism* or hematoma* or haematoma*)):ti,ab
#6.	(OR #1-#5)
#7.	MeSH descriptor: [Hydrocephalus] explode all trees
#8.	(hydrocephalus or hydrocephaly):ti,ab
#9.	water on the brain.ti,ab
#10.	(or #7-#9)
#11.	#6 and #10

B.2.2 Health Economics literature search strategy

3 Health economic evidence was identified by conducting a broad search relating to
 4 subarachnoid haemorrhage population in NHS Economic Evaluation Database (NHS EED –
 5 this ceased to be updated after March 2015) and the Health Technology Assessment
 6 database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the
 7 Centre for Research and Dissemination (CRD). Additional searches were run on Medline and
 8 Embase.

9 Table 6: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2003 – 23 June 2020	Exclusions Health economics studies
Embase	2003 – 23 June 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 23 June 2020 NHSEED - Inception to March 2015	None

10 Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)):ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp Intracranial Aneurysm/

5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	limit 25 to English language
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/27-42
44.	26 and 43

1 Embase (Ovid) search terms

1.	subarachnoid hemorrhage/
----	--------------------------

2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	limit 23 to English language
25.	health economics/
26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.
32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	24 and 38

1 NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Subarachnoid Hemorrhage EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Intracranial Hemorrhages EXPLODE ALL TREES


#3.	(((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)))
#4.	((SAH or aSAH))
#5.	#1 OR #2 OR #3 OR #4
#6.	MeSH DESCRIPTOR Aneurysm EXPLODE ALL TREES
#7.	((aneurysm* or hematoma* or haematoma*))
#8.	#6 OR #7
#9.	MeSH DESCRIPTOR Intracranial Aneurysm EXPLODE ALL TREES
#10.	(((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (aneurysm* or hematoma* or haematoma*)))
#11.	#9 OR #10
#12.	MeSH DESCRIPTOR Aneurysm, ruptured
#13.	(((ruptur* or weak* or brain or trauma*) adj3 (aneurysm* or hematoma* or haematoma*)))
#14.	#12 OR #13
#15.	(#5 or #8 or #11 or #14)

1

2

1 Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of detecting hydrocephalus



2
3

1 **Appendix D: Clinical evidence tables**

2 No evidence was identified for this review

3

1 **Appendix E: Coupled sensitivity and** 2 **specificity forest plots and sROC curves**

E.13 Coupled sensitivity and specificity forest plots

4 No evidence was identified for this review.

E.25 ROC curves


6 No evidence was identified for this review.

E.37 Area under the curve

No evidence was identified for this review.

1 **Appendix F: Health economic evidence** 2 **selection**

Figure 2: Flow chart of health economic study selection for the guideline



1 **Appendix G: Health economic evidence tables**

2 None.

3

1 Appendix H: Excluded studies

H.1.2 Excluded clinical studies

3 **Table 7: Studies excluded from the clinical review**

Reference	Reason for exclusion
Andaluz 2008 ¹	Inappropriate study design – no relevant outcomes
Duong 1996 ²	Inappropriate study design – case series
Łuczywek 2000 ³	Paper not in English
Mortimer 2016 ⁴	Inappropriate study design – no relevant outcomes
Ohmichi 2018 ⁷	Inappropriate comparison – assessment of hyperperfusion
Pascual 2008 ⁸	Inappropriate population – headaches provoked by cough
Peschillo 2017 ⁹	Inappropriate comparison – flow diversion vs coiling
Stadlbauer 2012 ¹⁰	Inappropriate comparison – MR mapping
Woodfield 2014 ¹¹	Inappropriate study design – unclear methodology

4

H.2.5 Excluded health economic studies

6 Published health economic studies that met the inclusion criteria (relevant population,
7 comparators, economic study design, published 2003 or later and not from non-OECD
8 country or USA) but that were excluded following appraisal of applicability and
9 methodological quality are listed below. See the health economic protocol for more details.

10 **Table 8: Studies excluded from the health economic review**

Reference	Reason for exclusion
None.	

11